GlassScriptPhysician profile
Dron Gauchan
NPI 1487805784
$61,803.74
in general payments reported to CMS, 2019-2025
23 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $16K · 2021: $12K · 2022: $3,477 · 2023: $623 · 2024: $758 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.56 |
| Education | $109.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30,984.34 | 2019-2025 | Calquence, Tagrisso, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $20,570.62 | 2019-2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $2,915.00 | 2020-2021 | |
| Novocure INC. | $2,672.60 | 2019-2025 | |
| Celgene Corporation | $1,854.53 | 2022-2025 | Reblozyl |
| Amgen INC. | $585.75 | 2019-2025 | Imdelltra (Amg757), Lumakras, Blincyto |
| Pfizer INC. | $405.24 | 2019-2025 | |
| Genzyme Corporation | $296.82 | 2023-2025 | |
| Astellas Pharma US INC | $229.67 | 2022-2025 | Vyloy |
| Janssen Biotech, INC. | $193.88 | 2022-2024 | Rybrevant |
| Seagen INC. | $170.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $162.16 | 2023-2025 | |
| Tempus Ai, INC | $160.99 | 2024 | Xt Cdx |
| Histosonics, INC. | $138.52 | 2025 | |
| Adaptive Biotechnologies Corporation | $90.29 | 2025 | Clonoseq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $83.27 | 2021 | |
| Eisai INC. | $66.76 | 2022-2024 | |
| Caris Mpi, INC. | $62.96 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $49.57 | 2025 | Mektovi, Braftovi, Tukysa |
| Sobi, INC | $29.62 | 2024 | |
| Daiichi Sankyo INC. | $29.23 | 2025 | Datroway |
| Abbvie INC. | $26.15 | 2023 | |
| Servier Pharmaceuticals LLC | $24.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dron Gauchan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.